Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population

Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 in PD-L1-Selected Population

Percentage of Participants Who Died of Any Cause in ITT Population

(and 32 more...)

915

All

18 Years and older (Adult, Older Adult)

NCT02420821

WO296372014-004684-20

IMmotion151

May 20, 2015

September 29, 2017

December 1, 2021

April 20, 2015

February 25, 2019

October 3, 2018

University of Arizona Cancer CenterTucson, Arizona, United States

University of California at Irvine Medical Center; Department of OncologyOrange, California, United States

Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase

175

All

1 Month to 3 Years (Child)

NCT02072824

A00810422013-003420-37

September 16, 2014

March 13, 2018

March 13, 2018

February 27, 2014

October 9, 2018

October 9, 2018

Pediatric Epilepsy Center of Central FloridaOrlando, Florida, United States